ImmunOs Therapeutics AG is making significant strides in the field of oncology with its groundbreaking approach to immunotherapy. The company is thrilled to announce that it has successfully raised **$65 million** in funding, which will catalyze the development of its innovative therapies aimed at harnessing the innate immune system to combat cancer and autoimmune diseases. This funding will specifically support the advancement of their lead program, iosH2, which is currently progressing into Phase 1 clinical trials. iosH2 is a multi-functional fusion protein designed to block specific leukocyte immunoglobulin-like receptors (LILRBs), thereby unleashing the body’s natural anti-tumor immune responses across various cancer types.
What sets ImmunOs apart is its commitment to not only providing direct anti-tumor effects but also remapping the tumor microenvironment to significantly enhance the efficacy of existing immunotherapies. By targeting a portfolio of novel immunomodulatory proteins and immunoregulatory receptors, the company aims to improve responses to standard therapies, including checkpoint inhibitors and costimulatory agonists. The unique approach holds the potential to revolutionize treatment paradigms and offers hope for patients who are battling advanced cancer. With this crucial injection of capital, ImmunOs Therapeutics AG is poised to accelerate its pioneering research and deliver innovative solutions to the oncology landscape, ultimately driving forward the future of cancer treatment.
.png&w=3840&q=75)
